BGPT: Paper Review: The complex roles of efferocytosis in cancer development, metastasis, and treatment

Explore by Goal

Quick Answer Copied

Core takeaway: This review frames efferocytosis as a context-dependent “double-edged” immune-clearing program—often tolerogenic (supporting tumor survival/metastasis), yet sometimes enabling anti-tumor immunity depending on whether apoptotic/necrotic fates, receptor usage, and downstream cytokine programs tilt toward suppression or immunogenicity.

Long Answer

Paper Review (Narrative): The complex roles of efferocytosis in cancer development, metastasis, and treatment

DOI: 10.1016/j.biopha.2021.111776 • Published: 2021-05-29

Scope: efferocytosis signals → TAM phenotypes → treatment outcomes Type: literature review (no new primary experiments)

1) Visual: the review’s mechanistic map (who talks to whom)

Evidence basis: This conceptual diagram is built from the paper’s described multi-step efferocytosis framework (“find-me / eat-me / don’t-eat-me”, engulfment, processing, tolerogenic responses) and its cancer-relevant extensions (TAM polarization; immunosuppressive mediators; and therapy-induced apoptotic debris shaping residual tumor behavior).

2) Visual: “pro-tumor vs anti-tumor” bifurcation logic

Critical note (skeptical): The bar heights above are not quantitative effect sizes; they are a visualization of the review’s directional emphasis (tolerogenic clearance can impair anti-tumor immunity; secondary necrosis can trigger immune activation or harm depending on context). The paper repeatedly stresses context dependence and controversies, but it does not provide a unified meta-analytic quantitative synthesis.

3) Detailed review of the paper’s structure (what it claims, and what’s uncertain)

3.1 Introduction & thesis

The review defines efferocytosis as clearance of apoptotic cells without inflammatory responses, and positions it as a regulator of inflammation resolution and self-tolerance.
In cancer therapy, inducing apoptotic tumor cells is argued to be a “double-edged sword”: apoptotic debris can be cleared tolerogenically and contribute to tumor persistence/recurrence/metastasis under some circumstances.

3.2 Mechanistic core: “find-me / eat-me / don’t-eat-me”

The review partitions efferocytosis into five steps: detection/find-me signals, recognition/eat-me and don't-eat-me signals, engulfment, processing, and anti-inflammatory/tolerance responses.
“Don’t-eat-me” biology (especially CD47–SIRPα) is described as a brake on phagocytosis, with tumor overexpression enabling immune evasion.

3.3 Cancer links the review emphasizes (TAM receptors, PS/calreticulin, immunosuppressive cytokines)

The review highlights efferocytosis-associated molecules as cancer-relevant, including phosphatidylserine (PS), calreticulin, and the TAM receptor family (Tyro3, Axl, MerTK), plus bridging molecules (Gas6/Protein S) and immunosuppressive cytokines (e.g., IL-10, TGF-β) in shaping the tumor microenvironment.
It also claims that therapy-induced apoptotic tumor cells can create conditions that limit cytotoxic efficacy by promoting efferocytosis, M2 polarization, and immunosuppression, potentially facilitating recurrence/metastasis.

4) Visual: targets/pathways and their implied immune directionality

The table below extracts the review’s target list (as described in its abstract and sections) and maps it to the directionality emphasized by the review: immunosuppression vs immunogenic activation. (This is a conceptual mapping, not a quantitative direction-score.)

Module (reviewed)	Role in efferocytosis (as stated)	Review’s emphasized effect in cancer/TME	Key therapeutic angle in the review
PS & calreticulin	Eat-me signals that enhance clearance/efferocytosis of apoptotic targets	Can contribute to tolerogenic clearance of therapy-induced apoptotic tumor cells	Block/target PS-mediated “eat-me” to restore anti-tumor activity
CD47–SIRPα	Don’t-eat-me axis suppressing phagocytosis	Tumors overexpress CD47 to inhibit cancer cell recognition/killing	CD47 blockade to enhance phagocytosis and improve therapy outcomes
TAM receptors (MerTK, Axl, Tyro3)	Bridge ligand–dependent receptors supporting efferocytosis programs	Can promote M2 polarization, immunosuppression, and therapy resistance	Inhibit TAM signaling to reduce tumor-promoting immune states
Gas6 / Protein S bridging	Bridges PS to TAM receptors	Supports oncogenic and immune-inhibitory signaling	Neutralize/interrupt bridging to block efferocytosis-driven tolerance
HMGB1 (alarmin) & inflammatory signaling	DAMP-related immune modulation; context-dependent pro/anti-tumor roles	Can influence immunogenic cell death vs immunosuppression depending on clearance kinetics	Modulate HMGB1 signaling balance to improve therapy efficacy

Evidence basis: This mapping is drawn from the review’s own target/receptor/cytokine descriptions (abstract + sections). It should not be interpreted as a validated causal ranking; the paper itself stresses controversies and context dependence.

5) Critical appraisal (skeptical, mechanistic, and falsification-oriented)

5.1 Strengths

Coherent mechanistic scaffolding: the review consistently uses the five-step efferocytosis decomposition (find-me → eat-me/don’t-eat-me → engulfment → processing → anti-inflammatory/tolerance).
Direct therapy linkage: it repeatedly connects treatment-induced apoptotic tumor cells (ATCs) with subsequent efferocytosis competence and macrophage polarization, arguing for a plausible route by which therapy could inadvertently promote residual tumor fitness.
Target-centric synthesis: the paper names multiple tractable axes (CD47, TAM receptors, PS/calreticulin, HMGB1, IL-10/TGF-β) and discusses the potential benefit/risks of modulating each.

5.2 Limitations & blind spots (what could mislead a reader)

Narrative (non-systematic) synthesis: the paper is a narrative review, so it can’t control for selection bias, heterogeneity of models, and uneven reporting of effect directions across contexts.
Context-dependence is emphasized, but quantification is missing: the review recognizes controversies about the utility of efferocytosis against treatment-induced apoptotic cells, yet it does not provide a quantitative framework that predicts when efferocytosis flips from tolerogenic to immunogenic.
Risk tradeoffs may be under-specified: targeting efferocytosis can, in principle, increase inflammation, tissue injury, or autoimmunity if clearance becomes incomplete; the review notes this risk in principle. However, readers are not given unified safety bounds across tissues and time.

6) What evidence would most falsify the review’s central framing?

If efferocytosis modulation does not shift residual tumor immune states (e.g., no consistent change in tolerogenic cytokine signatures or macrophage phenotypes) across multiple cancer contexts, the causal chain “ATCs → efferocytosis → tolerogenic TME → metastasis/recurrence” would be weakened.
If blocking specific axes (CD47, TAM receptors, PS/calreticulin) reliably worsens clearance without improving therapy outcomes, the therapeutic targeting strategy would become less compelling.

Explore author-specific perspectives: (Open separate BGPT author review pages)

Feedback:

Updated: April 02, 2026